Early sepsis detection: molecular immune markers show limited impact in screening tools

Researchers evaluated the additional predictive value of molecular immune markers with the Predict Sepsis screening tools developed previously by the same research team.

AEVIS VICTORIA SA – Visana Beteiligungen AG becomes a shareholder of Swiss Medical Network SA – Biotech Investments

AEVIS VICTORIA SA / Key word(s): Agreement 11-Jul-2023 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is

July 12, 2023

Risk adjusted net present value: What is the current valuation of Johnson & Johnson’s PN-235?

PN-235 is a synthetic peptide commercialized by Johnson & Johnson, with a leading Phase III program in Plaque Psoriasis (Psoriasis Vulgaris).

March 14, 2024

Aclaris loses 85% of share value after another PhII setback in inflammatory condition

Aclaris Therapeutics’ lead drug has failed another mid-stage test, marking the biotech’s second major setback this year and the autoimmune treatment’s final shot in the

November 14, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.